Radiopharm expands team-up with GenesisCare to trial cancer meds in Australia
Radiopharm Theranostics has called on GenesisCare to help it trial is pipeline of candidate radiopharmaceutical in Australia.
The partnership will see Genesis run Phase I trials of three radiopharmaceutical candidates at various clinical and cancer research sites across Australia that are being developed by Radiopharm.
The specific candidates will be a PDL-1 targeting nano-mAb for non-small cell lung cancer; a PTPu targeting peptide for brain tumors; and an antibody that targets PSA in prostate cancer.
Radiopharmaceuticals are designed to deliver small doses of radiation to specifically targeted cells for either therapeutic or diagnostic purposes, referred to as theranostics when used in concert.
And, according to Radiopharm Theranostics CEO Riccardo Canevari interest in such therapies is increasing.
“Radiopharmaceuticals are quickly becoming a highly promising therapeutic frontier in oncology, offering new hope to patients who may have exhausted all other treatment options.”
“We are delighted to be extending and strengthening our partnership with GenesisCare, a world leader in cancer care, to advance the future of radiopharmaceuticals and improve access to innovative therapies for patients all over the world.”
This view was echoed by GenesisCare chief scientific officer Danielle Meyrick, who said “We are delighted to be partnering with Radiopharm on its exciting pipeline of research in Australia.
Meyrick added “This R&D collaboration brings together two Australian-founded health companies who share an interest in investigating and developing new therapies.”
GenesisCare has more than 440 locations in Australia, UK, the US, and Spain.
Radiopharm Theranostics has worked with the clinical research organization (CRO) since last March when the firm’s signed a letter of intent covering early phase trials of the PDL-1 targeting nano-mAb.
And last July they extended and agreement to run trials of Radiopharm’s PSA targeting antibody.
Extension of the agreement with GenesisCare comes less than a month after Radiopharm acquired Pharma15 Corp, a US-based developer of radiopharmaceutical for the treatment of prostate cancer.
DepositPhotos/janaka